Welcome to our dedicated page for Valneva Se SEC filings (Ticker: VALN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Valneva SE (VALN) is a French specialty vaccine company that reports to the U.S. Securities and Exchange Commission as a foreign private issuer. Its SEC filings, primarily on Form 20-F and Form 6-K, provide detailed insight into the company’s vaccine portfolio, segment reporting, financing arrangements and material agreements.
Through these filings, investors can review Valneva’s segment information, which distinguishes between Commercialized vaccines (including IXIARO/JESPECT, DUKORAL and IXCHIQ), Covid activities, Vaccine candidates and Technologies and services. Interim condensed consolidated financial statements filed on Form 6-K include revenue breakdowns by product groups, geographies and revenue types such as product sales, royalties, shipping and handling, milestone payments and other product-related income.
Valneva’s SEC reports also disclose key collaboration and financing structures. Examples include the amended collaboration and license agreement with Pfizer for the Lyme disease vaccine candidate VLA15, strategic partnership agreements related to chikungunya vaccine IXCHIQ, and loan agreements providing senior term loan facilities to refinance prior credit arrangements and fund general corporate and working capital requirements. These documents outline covenants, security interests over assets and intellectual property, and the role of subsidiaries that guarantee the company’s obligations.
On this page, Stock Titan surfaces Valneva’s latest SEC submissions as they are posted to EDGAR, including current reports on Form 6-K that furnish press releases, financial statements and business updates. AI-powered summaries help explain the key points of lengthy filings, such as changes in debt financing, updates to collaboration terms, or new clinical and regulatory disclosures. Users can quickly identify items related to vaccine segment performance, major agreements, and risk factor discussions without reading every page.
In addition to financial and operational information, Valneva’s filings may reference research tax credit arrangements, strategic partnerships with organizations such as the Coalition for Epidemic Preparedness Innovations (CEPI), and the structure of its international subsidiaries. This SEC filings page is designed to make those disclosures easier to navigate, with real-time updates and AI-generated highlights that point to the most relevant sections for vaccine-focused investors.
Valneva SE, a specialty vaccine company, plans to report its full year 2025 consolidated financial results on March 18, 2026. The company will host a live webcast at 3 p.m. CET / 10 a.m. EDT to discuss the results and provide a business update.
The webcast will be available on Valneva’s website and archived after the event. The filing also reiterates Valneva’s focus on developing and commercializing vaccines for infectious diseases, including advanced candidates for Lyme disease and Shigella.
Valneva SE reported that its senior management will participate in several upcoming investor conferences in the United States and Europe. CEO Thomas Lingelbach and CFO Peter Buhler plan to present the company’s key value drivers and upcoming milestones, including the topline Phase 3 data readout for VLA15, Valneva’s Lyme disease vaccine candidate partnered with Pfizer, which Pfizer expects to report in the first half of 2026.
Events include a webcasted presentation and investor meetings at the TD Cowen 46th Annual Health Care Conference in Boston, and investor meetings at conferences hosted by Jefferies in Miami and Van Lanschot Kempen in Amsterdam.
Valneva reported preliminary unaudited 2025 revenue of €174.7 million, slightly above 2024’s €169.6 million, including €157.9 million in product sales. While reported product sales declined from €163.3 million, they rose 9% at constant exchange rates excluding third‑party sales. Cash and cash equivalents were €109.7 million as of December 31, 2025, down from €168.3 million a year earlier.
For 2026, Valneva expects total revenues of €155‑170 million, with product sales of €145‑160 million, reflecting growth in core brands but a wind‑down of third‑party sales. A potentially transformational Phase 3 data readout for Lyme disease vaccine candidate VLA15 is anticipated in the first half of 2026, and first Phase 2 data for its tetravalent Shigella vaccine S4V2 are expected, with a development decision in the second half of 2026. The Board renewed co‑founder Thomas Lingelbach’s Chief Executive Officer mandate for a further three‑year term, supporting leadership continuity.
Valneva SE reported that the United Kingdom’s Commission on Human Medicines has updated its recommendations for use of its single-dose chikungunya vaccine IXCHIQ®. The revised prescribing information adds restrictions for people over 60 years of age, for individuals with specified health conditions, and on timing of vaccination before travel.
The UK regulator confirmed that IXCHIQ’s benefit–risk profile remains favorable for people aged 18 to 59 years who are at risk of chikungunya infection and do not have the contraindicated underlying conditions. The update follows a temporary suspension of use in older individuals after serious adverse events were reported mainly in elderly people with significant underlying medical issues during an outbreak vaccination campaign on La Reunion. Valneva states it will continue monitoring post‑marketing safety data and work with authorities on any further adjustments.
Valneva SE has filed a Form 6-K highlighting a new collaboration step with Instituto Butantan in Brazil. The partners are launching a Pilot Vaccination Strategy using Valneva’s single-shot chikungunya vaccine IXCHIQ® across ten Brazilian municipalities selected on epidemiological and operational criteria.
The program, targeting adults aged 18 to 59 years, aims to reach 20% to 40% vaccine coverage in the eligible population. Valneva will supply the initiative by donating up to 500,000 doses of IXCHIQ® through Instituto Butantan to Brazil’s Ministry of Health. This pilot will generate post-marketing, real-world effectiveness and safety data in an endemic setting, building on Brazil’s prior marketing approval of IXCHIQ® for adults in April 2025.
Valneva SE reports that it has voluntarily withdrawn the U.S. biologics license application (BLA) and Investigational New Drug (IND) application for its chikungunya vaccine IXCHIQ®. This follows the U.S. FDA’s earlier suspension of the IXCHIQ license in August 2025 and a more recent FDA decision to place the IND on clinical hold while it investigates a newly reported serious adverse event (SAE) from outside the U.S.
The SAE involved a younger adult who received three vaccines at the same time, including IXCHIQ; based on available data, the case may be plausibly related to IXCHIQ, but causality has not been determined. Valneva states that no IXCHIQ clinical studies are currently vaccinating participants and that it plans to continue post-marketing clinical activities after further discussions with regulators. The company continues to supply IXCHIQ in territories where it is licensed, including Europe, Canada, the United Kingdom and Brazil, and maintains that the vaccine’s benefit–risk profile remains favorable, particularly for people in endemic and outbreak settings.
Valneva SE filed a Form 6-K to furnish a press release announcing that its management will meet investors during the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12–14, 2026. The company plans one-on-one meetings with existing shareholders and discussions with other institutional specialist investors.
CEO Thomas Lingelbach and CFO Peter Bühler will present upcoming catalysts from Valneva’s clinical pipeline, including a pivotal data readout for its Lyme disease vaccine in the first half of the year, and will also discuss its commercial vaccine portfolio. Valneva describes itself as a specialty vaccine company with three proprietary travel vaccines on the market and a pipeline that includes a Lyme disease vaccine candidate partnered with Pfizer and a tetravalent Shigella vaccine candidate.
Valneva SE furnished a Form 6-K as a foreign private issuer to provide investors with a press release and unaudited interim condensed consolidated financial statements dated November 26, 2025. These materials, attached as Exhibit 99.1, present the company’s latest results and are incorporated by reference into its existing Form F-3 shelf registration statement.
Valneva SE filed a Form 6-K reporting that it has released its results for the three months ended September 30, 2025. The company furnished a press release and unaudited interim condensed consolidated financial statements as exhibits, providing more detail on its recent quarterly performance.
Most of the information in this Form 6-K, excluding the section titled “Financial Outlook” in the press release, is incorporated by reference into Valneva’s existing Form F-3 registration statement. This means those disclosures can now be used in connection with Valneva’s registered securities offerings in the United States.